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Protein drugs, because of their large size and hydrophilic
nature, are normally precluded from effective delivery such as
cell entry or tissue diffusion. Among the transport barriers,
the skin poses a formidable challenge to proteins because of
the impermeable stratum corneum. The existing techniques
for percutaneous protein delivery must rely on sophisticated
delivery systems, such as the use of complicated nanocarriers
or mechanical devices, to overcome the skin barrier for
noninvasive delivery. A challenge in manufacturing such
systems is the complicated processes and potential negative
impact on protein drug stability. Moreover, the high manu-
facturing cost of these advanced systems often offsets their
remarkable advantages.
To circumvent these problems that confront the current
methods, we hypothesized the concept of “skin-permeable
proteins”, which would possess skin-penetrating ability and
thereby eliminate the need for a transport vehicle. However,
naturally occurring proteins with skin-penetrating ability are
rare. Herein, we present a novel strategy for chemically
constructing artificial skin-permeable proteins, illustrated by
the simple conjugation of a protein to a cell-penetrating
peptide (CPP), which would display a penetration effect on
the stratum corneum barrier and transport the attached
proteins into the skin. Furthermore, the feasibility of appli-
cation of the strategy in transcutaneous immunization (TI) is
demonstrated.
CPPs are known for their versatility in carrying macro- or
supramolecules through the cell membrane barriers that
challenge the conventional drug-delivery approaches.[1] The
CPPs are capable of transporting their cargos, often linked by
a covalent bond, into almost all cell types.[2] Among such
CPPs, the low-molecular-weight protamine (LMWP) peptide
(VSRRRRRRGGRRRR), developed in our laboratory by
enzymatic digestion of protamine (an FDA-approved drug),
offers distinct advantages. First, LMWP is as potent as the
virus-derived TAT peptide, the most-studied CPP to date, in
mediating cellular translocation of the attached cargos.[3]
Secondly, unlike other CPPs, the toxicity profile of LMWP
has already been thoroughly established. LMWP was shown
to be nonimmunogenic,[4] and its use in dogs did not elicit
acute toxic responses.[5] Lastly, while other CPPs must be
chemically synthesized, LMWP can be produced in mass
quantities direct from native protamine with limited process-
ing time and cost.[6]
In this investigation, the artificial skin-permeable protein
was synthesized by conjugating LMWP to ovalbumin (OVA),
a representative antigenic protein, through a cleavable
disulfide bond (Scheme 1). The LMWP–OVA conjugates
were purified by heparin affinity chromatography, and the
final product, generally possessing a 1:1 molar ratio of
LMWP/OVA, was verified by MALDI-TOF mass spectrom-
etry.
As noted, skin keratinocytes are a physical barrier that
provides the front line of defense against infection and also
poses a challenge to protein delivery. On the other hand,
keratinocytes execute a “part-time” antigen-presenting func-
tion by secreting immune mediators and transferring antigens
to local antigen-presenting cells.[7] LMWP was shown to
Scheme 1. Chemical conjugation of LMWP to OVA. SPDP= N-succini-
midyl-3-(2-pyridyldithio)propionate.
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exhibit an ability to translocate linked cargos of varying sizes
into keratinocytes (Figure 1), thus demonstrating the poten-
tial for percutaneous protein delivery.
The plausibility of percutaneous delivery in vivo was
examined by topical application of LMWP-linked lysozyme,
OVA, or bovine serum albumin (BSA), to represent a broad
range of protein sizes. All the LMWP-linked proteins
successfully penetrated the stratum corneum and accumu-
lated primarily in the epidermis (Figure 2), whereas the
control proteins without LMWP linkage remained on the
surface of the skin.
The skin penetration mechanism of CPPs is still under
debate. However, the interaction between CPP and the lipid
bilayer is believed to play a major role in the cell penetration
process.[8] Skin permeability is governed by the physical state
and structural organization of the extracellular lipids.[9]
Hence, the skin penetration function of LMWP could account
for its interaction with the skin extracellular lipid matrices.
Such interaction would lead to disruption of the ordered lipid
orientation, thereby creating channels for transducing protein
cargos through the stratum corneum.
As a typical example of protein percutaneous delivery, the
immunological milieu of the skin is an ideal site for non-
invasive vaccine delivery. The epidermis is rich in mature
Langerhans cells (LCs), which represent a network of
immune cells that underlie 25% of the total surface area in
human skin,[10] and thus the epidermis is the target skin layer
for TI. TI can be achieved by topically applying antigens,
which, with the aid of a transdermal delivery system,
penetrate into the skin and subsequently elicit the desired
immunity. The network of LCs acts as an immunological line
of defense and initiates immune responses by conveying the
captured antigens to other cells of the immune system, for
example, lymphocytes, melanocytes, and Mercel cells.[11]
Therefore, the unique epidermal accumulation of the
LMWP-linked proteins offers an ideal situation to alert such
antigen-presenting cells.
The constructed skin-permeable antigen of LMWP–OVA
was tested for the feasibility of TI on Balb/c mice. Humoral
immunoglobulin G (IgG) is the primary protection induced
by preventive vaccines to neutralize and eliminate pathogens.
Figure 3a revealed that a significant elevation of anti-OVA
IgG concentration in the blood was observed following
topical application of LMWP–OVA with cholera toxin as
adjuvant. The IgG levels in TI groups treated with a high (TI-
H) and medium dose (TI-M) of antigen displayed no
statistical differences (p> 0.05) from those in animals given
OVA through the standard intramuscular (IM) immunization
method (IM group). The control group, which received
topical native OVA, exhibited markedly lower levels of IgG
as a result of poor percutaneous absorption of unmodified
OVA. These findings indicated that the epidermis-accumu-
lated LMWP–OVA was captured by LCs, which subsequently
migrated to lymphoid tissues and presented the antigens,
effectively eliciting robust humoral immune responses. Fur-
thermore, the disulfide linkage could be cleaved by the
Figure 1. Uptake by human keratinocyte cells of a) rhodamine B,
b) OVA, and c) bovine serum albumin (BSA) compared with those of
d) LMWP–rhodamine B, e) LMWP–OVA, and f) LMWP–BSA conju-
gates. Protein cargos were labeled with fluorescein isothiocyanate.
Figure 2. In vivo transcutaneous delivery mediated by LMWP.
a–c) Unmodified free lysozyme, OVA, and BSA, respectively;
d–f) LMWP-linked lysozyme, OVA, and BSA, respectively. Arrows
represent the direction of skin penetration.
Angewandte
Chemie
2725Angew. Chem. Int. Ed. 2010, 49, 2724 –2727  2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
elevated level of glutathione and reductase activity in the
cytosol,[12] which allowed release of OVA from LMWP and
thus retention of a full intrinsic immunogenicity. As evidence,
LMWP–OVA in the TI method triggered OVA-specific IgG
responses comparable to the IM injection of OVA. Since the
conjugation of LMWP to OVA might affect its intrinsic
antigenic determinants, a cleavable linkage could ease such
concerns.
TI shows advantages over conventional injection vacci-
nation by offering the opportunity to elicit specific immune
responses, such as targeted immunity to the female repro-
ductive tract[13] and a cytotoxic T lymphocyte (CTL) effect.[14]
Secretory immunoglobulin A (sIgA) is the predominant
humoral defense mechanism at the mucosal surface, and it
therefore protects the host from initial infections. As shown in
Figure 3b, the anti-OVA sIgA levels measured in vaginal
secretions were significantly higher in the TI-H and TI-M
groups than those in the IM group, thus confirming the
promise of TI in achieving local protective immunity against
female genital infection. Furthermore, interferon-g (IFN-g),
the representative cytokine known to enhance the CD8+
CTL-mediated cytotoxicity against infected cells, was also
present at a level significantly higher in the TI groups than in
the IM group (Figure 3c). Notably, the local immune
response in skin could also benefit from the production of
high levels of IFN-g, because of its effect on promoting CTL
recognition of antigen molecules in keratinocytes[15] and
subsequently their expedited lysis.[16]
In addition, a primer–booster vaccination conducted by
combining the IM injection of OVA with transcutaneous
boosters of LMWP–OVA showed an immunity induction
comparable to that of the multishot IM standard method
(Supporting Information, Figure S1). The self-administrable
boosters would eliminate follow-up visits to clinics for a
multidose protocol. Hence, this immunization strategy could
improve not only patient compliance but also vaccination
coverage in underserved areas with limited medical settings.
In conclusion, this methodology for constructing artificial
skin-permeable antigens may offer simple and needle-free
vaccination modalities without the need for sophisticated
drug carriers or expensive medical devices. Such a method
could be beneficial especially to developing countries that
struggle to fulfill effective vaccination coverage.
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